Alnylam, Medtronic to Get Funding for Huntington's Disease Program

Alnylam said that the non-profit CHDI Foundation has agreed to pay up to 50 percent of the costs of advancing a treatment for the disease up through an investigational new drug application filing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.